National Securities Initiates Coverage on Dyax (DYAX) with a Buy
More News related to DYAX
- DX-88 (ecallantide) Demonstrated Relief of Symptoms in Hereditary Angioedema Acute Attacks in All Attack Locations
- National Securities Initiates Coverage on Dyax (DYAX) with a Buy
- Trading Radar for 10/28: First Solar (FSLR), ConocoPhillips (COP), WellPoint (WLP), Goodyear (GT), Int. Paper (IP) Report
- Dyax Corp. (DYAX) Posts Q3 Loss of $0.17, Wider Than Expected
- Dyax Corp. Announces Third Quarter 2009 Financial Results
More News related to New Coverage
- Best of the Web 11/23: Suicides On the Rise, U.S. Debt Service Could Top $700B, Really? An Insider Trading Beauty Queen
- Notable Analyst Rating Changes 11/23: SBUX, DE, SEED, NDAQ Upgraded; AGU, TRA, CIEN, FL Downgraded
- Notable Mergers and Acquisitions of the Day 11/23: GMCR/DDRX, PBCT/FIF, CIEN, BDX, IDTI
- Morning Movers 11/23: ABIO, SEED, FIF, FNET, DDRX, JOBS Higher; BBI, CGA, BOFL, CEPH Lower
National Securities initiates coverage on Dyax (Nasdaq: DYAX) with a Buy. Price target $5.
To see more analyst ratings on DYAX Click Here.
Dyax Corp., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of biotherapeutics for oncology and inflammatory indications.
Related Categories
New CoverageStocks Mentioned
+0.05Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
